Switch theme
Sign up to access all valuation multiples
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
1998
3.4K+
LTM Revenue $1.2B
LTM EBITDA $243M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tasly has a last 12-month revenue of $1.2B and a last 12-month EBITDA of $243M.
In the most recent fiscal year, Tasly achieved revenue of $1.2B and an EBITDA of $224M.
Tasly expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tasly valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | XXX | XXX | XXX |
| Gross Profit | $758M | $798M | XXX | XXX | XXX |
| Gross Margin | 63% | 68% | XXX | XXX | XXX |
| EBITDA | $249M | $224M | XXX | XXX | XXX |
| EBITDA Margin | 21% | 19% | XXX | XXX | XXX |
| Net Profit | -$35.3M | $148M | XXX | XXX | XXX |
| Net Margin | -3% | 13% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Tasly's stock price is CNY 15 (or $2).
Tasly has current market cap of CNY 22.5B (or $3.1B), and EV of CNY 20.7B (or $2.8B).
See Tasly trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $3.1B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Tasly has market cap of $3.1B and EV of $2.8B.
Tasly's trades at 2.4x LTM EV/Revenue multiple, and 11.7x LTM EBITDA.
Analysts estimate Tasly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Tasly and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | XXX | XXX |
| P/E | 23.6x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | 14.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTasly's NTM/LTM revenue growth is 5%
Tasly's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Tasly's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Tasly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Tasly and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 50% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tasly acquired XXX companies to date.
Last acquisition by Tasly was XXXXXXXX, XXXXX XXXXX XXXXXX . Tasly acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Tasly founded? | Tasly was founded in 1998. |
| Where is Tasly headquartered? | Tasly is headquartered in China. |
| How many employees does Tasly have? | As of today, Tasly has 3.4K+ employees. |
| Is Tasly publicy listed? | Yes, Tasly is a public company listed on SHG. |
| What is the stock symbol of Tasly? | Tasly trades under 600535 ticker. |
| When did Tasly go public? | Tasly went public in 2002. |
| Who are competitors of Tasly? | Similar companies to Tasly include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tasly? | Tasly's current market cap is $3.1B |
| What is the current revenue of Tasly? | Tasly's last 12-month revenue is $1.2B. |
| What is the current EBITDA of Tasly? | Tasly's last 12-month EBITDA is $243M. |
| What is the current EV/Revenue multiple of Tasly? | Current revenue multiple of Tasly is 2.4x. |
| What is the current EV/EBITDA multiple of Tasly? | Current EBITDA multiple of Tasly is 11.7x. |
| What is the current revenue growth of Tasly? | Tasly revenue growth between 2023 and 2024 was -2%. |
| Is Tasly profitable? | Yes, Tasly is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
